MDGL Madrigal Pharmaceuticals Inc

$391.43

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/18/2025

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Website: https://www.madrigalpharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1157601
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, US
Valuation
Market Cap
$6.66B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
8.83
Performance
EPS
$-21.90
Dividend Yield
—
Profit Margin
-258.60%
ROE
-80.30%
Technicals
50D MA
$330.50
200D MA
$289.57
52W High
$377.46
52W Low
$189.00
Fundamentals
Shares Outstanding
22M
Target Price
$414.07
Beta
-0.69

MDGL EPS Estimates vs Actual

● Estimated
● Actual

MDGL News & Sentiment

Aug 18, 2025 • Benzinga SOMEWHAT-BULLISH
What's Going On With Novo Nordisk Stock Monday? - Novo Nordisk ( NYSE:NVO )
36.8% on Wegovy showed liver fibrosis improvement vs 22.4% on placebo at week 72. FDA approval adds MASH with liver fibrosis to Wegovy's indications. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. On Saturday, the U.S.
Aug 16, 2025 • Benzinga BULLISH
Billionaire Investor Buys Google And This Gold Miner Stock - Perpetua Resources ( NASDAQ:PPTA )
John Paulson's hedge fund, Paulson & Co., discloses the purchase of 9,000 shares of Alphabet. The also increases its position in gold miner Perpetua Resources. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing.
Aug 07, 2025 • Benzinga SOMEWHAT-BULLISH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc.
Aug 05, 2025 • Motley Fool SOMEWHAT-BULLISH
Madrigal ( MDGL ) Q2 Revenue Soars 1,313%
Madrigal Pharmaceuticals ( NASDAQ:MDGL ) , a biopharmaceutical firm focused on liver diseases, reported its second quarter 2025 earnings on August 5, 2025. The standout news in this release was an explosive surge in GAAP revenue to $212.8 million, sharply exceeding the consensus estimate of ...
Aug 05, 2025 • Benzinga NEUTRAL
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
Second-quarter 2025 Rezdiffra™ ( resmetirom ) net sales of $212.8 million As of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045 Announced global licensing agreement for an oral GLP-1 development candidate
Aug 05, 2025 • GlobeNewswire NEUTRAL
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today reports second-quarter 2025 financial results and ...
Sentiment Snapshot

Average Sentiment Score:

0.292
50 articles with scored sentiment

Overall Sentiment:

Bullish

MDGL Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
2.96 Surprise
  • Reported EPS: $-3.32
  • Estimate: $-6.28
  • Whisper: —
  • Surprise %: 47.1%
Feb 26, 2025
Dec 31, 2024 (Pre market)
1.41 Surprise
  • Reported EPS: $-2.71
  • Estimate: $-4.12
  • Whisper: —
  • Surprise %: 34.3%
Oct 31, 2024
Sep 30, 2024 (Pre market)
1.99 Surprise
  • Reported EPS: $-4.92
  • Estimate: $-6.91
  • Whisper: —
  • Surprise %: 28.8%
Aug 07, 2024
Jun 30, 2024 (Pre market)
0.43 Surprise
  • Reported EPS: $-7.10
  • Estimate: $-7.53
  • Whisper: —
  • Surprise %: 5.7%
May 07, 2024
Mar 31, 2024 (Pre market)
-1.1 Surprise
  • Reported EPS: $-7.38
  • Estimate: $-6.28
  • Whisper: —
  • Surprise %: -17.5%
Feb 28, 2024
Dec 31, 2023 (Pre market)
-0.4 Surprise
  • Reported EPS: $-5.68
  • Estimate: $-5.28
  • Whisper: —
  • Surprise %: -7.6%
Nov 06, 2023
Sep 30, 2023 (Pre market)
-0.41 Surprise
  • Reported EPS: $-5.34
  • Estimate: $-4.93
  • Whisper: —
  • Surprise %: -8.3%
Aug 08, 2023
Jun 30, 2023 (Pre market)
-0.11 Surprise
  • Reported EPS: $-4.69
  • Estimate: $-4.58
  • Whisper: —
  • Surprise %: -2.4%
May 09, 2023
Mar 31, 2023 (Pre market)
0.71 Surprise
  • Reported EPS: $-4.23
  • Estimate: $-4.94
  • Whisper: —
  • Surprise %: 14.4%

Financials